Payment overview · 2025
General Payments
$805.61
30 reported records · 16 companies
Healthcare provider profile · identity verified
William C. Aldrich, MD
Allopathic & Osteopathic Physicians|Family Medicine · MANNING, SC · NPI 1356458061
Verified facts
What the public records show
CMS Open Payments records show William C. Aldrich, MD received $805.61 in general payments during 2025 across 30 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Mounjaro, Ozempic, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 178 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 343 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 107 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $200.64 | 24.9% | 7 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $148.92 | 18.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $134.92 | 16.8% | 5 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $42.42 | 5.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $40.45 | 5.0% | 2 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $38.64 | 4.8% | 2 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $36.54 | 4.5% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.68 | 2.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.16 | 2.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.78 | 2.5% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.36 | 2.4% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $19.28 | 2.4% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $18.92 | 2.4% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $16.12 | 2.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $15.06 | 1.9% | 1 | 2025 |
| Optos, Inc. | Unresolved — no canonical attribution shown | $13.72 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $791.89 | 29 |
| Entertainment | $13.72 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $148.92 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $148.92 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $134.92 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $121.93 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $42.42 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.56 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.45 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $38.64 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $38.15 | 1 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $36.54 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $36.54 | 2 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $36.54 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $30.66 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.16 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.06 | 1 | 2025 |
Source payment records
|
|||||
| NFC-700 Normalized: nfc 700 |
Device | Optos, Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| OCT OPHTHALMOSCOPE Normalized: oct ophthalmoscope |
Device | Optos, Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
| PANORAMIC OPHTHALMOSCOPE Normalized: panoramic ophthalmoscope |
Device | Optos, Inc. | $13.72 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 268 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 343 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 122 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 107 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 189 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
178 | 44 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
268 | 48 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
48 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
11 | 11 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
189 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
122 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
343 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
97 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
107 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
189 | 44 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 841 | 215 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 810 | 94 |
| Pantoprazole Sodium | Pantoprazole Sodium | 613 | 155 |
| Losartan Potassium | Losartan Potassium | 503 | 139 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 458 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 446 | 117 |
| Atorvastatin Calcium | Atorvastatin Calcium | 445 | 133 |
| Furosemide | Furosemide | 347 | 100 |
| Mounjaro | Tirzepatide | 343 | 45 |
| Omeprazole | Omeprazole | 336 | 84 |
| Gabapentin | Gabapentin | 320 | 78 |
| Tramadol Hcl | Tramadol Hcl | 318 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 309 | 81 |
| Lisinopril | Lisinopril | 299 | 79 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 287 | 75 |
| Alprazolam | Alprazolam | 282 | 35 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 275 | 86 |
| Diclofenac Sodium | Diclofenac Sodium | 271 | 86 |
| Farxiga | Dapagliflozin Propanediol | 268 | 48 |
| Levothyroxine Sodium | Levothyroxine Sodium | 268 | 65 |
| Metformin Hcl | Metformin Hcl | 263 | 70 |
| Tamsulosin Hcl | Tamsulosin Hcl | 251 | 71 |
| Carvedilol | Carvedilol | 248 | 67 |
| Pregabalin | Pregabalin | 224 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 218 | 88 |
| Famotidine | Famotidine | 210 | 63 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 65 |
| Potassium Chloride | Potassium Chloride | 200 | 57 |
| Escitalopram Oxalate | Escitalopram Oxalate | 199 | 53 |
| Eliquis | Apixaban | 189 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 189 | 42 |
| Glimepiride | Glimepiride | 178 | 51 |
| Linzess | Linaclotide | 178 | 44 |
| Montelukast Sodium | Montelukast Sodium | 172 | 43 |
| Allopurinol | Allopurinol | 167 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 38 |
| Trazodone Hcl | Trazodone Hcl | 150 | 38 |
| Clonazepam | Clonazepam | 139 | 22 |
| Meloxicam | Meloxicam | 136 | 48 |
| Quetiapine Fumarate | Quetiapine Fumarate | 132 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 128 | 40 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 38 |
| Jardiance | Empagliflozin | 122 | 36 |
| Ozempic | Semaglutide | 122 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 121 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 119 | 54 |
| Topiramate | Topiramate | 112 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 111 | 24 |
| Fluconazole | Fluconazole | 107 | 35 |
| Promethazine Hcl | Promethazine Hcl | 107 | 28 |
| Rybelsus | Semaglutide | 107 | 24 |
| Trulicity | Dulaglutide | 97 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 89 | 29 |
| Xarelto | Rivaroxaban | 88 | 18 |
| Nifedipine Er | Nifedipine | 84 | 24 |
| Prednisone | Prednisone | 80 | 30 |
| Diazepam | Diazepam | 79 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 66 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 76 | 17 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 75 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 74 | 19 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 73 | 14 |
| Buspirone Hcl | Buspirone Hcl | 72 | 18 |
| Benazepril Hcl | Benazepril Hcl | 71 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 20 |
| Cilostazol | Cilostazol | 68 | 20 |
| Mirtazapine | Mirtazapine | 68 | 25 |
| Ezetimibe | Ezetimibe | 67 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 65 | 18 |
| Atenolol | Atenolol | 63 | 16 |
| Lorazepam | Lorazepam | 63 | 15 |
| Simvastatin | Simvastatin | 62 | 18 |
| Clonidine Hcl | Clonidine Hcl | 61 | 22 |
| Meclizine Hcl | Meclizine Hcl | 61 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 59 | 18 |
| Bupropion Hcl Sr | Bupropion Hcl | 58 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 58 | 16 |
| Spironolactone | Spironolactone | 57 | 17 |
| Entresto | Sacubitril/Valsartan | 56 | 16 |
| Baclofen | Baclofen | 55 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 55 | 17 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 54 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 17 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 54 | 12 |
| Celecoxib | Celecoxib | 52 | suppressed |
| Ketoconazole | Ketoconazole | 49 | 26 |
| Symbicort | Budesonide/Formoterol Fumarate | 48 | 12 |
| Amoxicillin | Amoxicillin | 47 | 41 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 46 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 12 |
| Azelastine Hcl | Azelastine Hcl | 45 | 26 |
| Colchicine | Colchicine | 45 | 18 |
| Estradiol | Estradiol | 45 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 12 |
| Gemfibrozil | Gemfibrozil | 43 | suppressed |
| Sucralfate | Sucralfate | 43 | 20 |
| Belsomra | Suvorexant | 39 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | suppressed |
| Aripiprazole | Aripiprazole | 38 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 38 | 15 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 38 | 16 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 37 | suppressed |
| Carisoprodol | Carisoprodol | 37 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 37 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Ibuprofen | Ibuprofen | 37 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 28 |
| Cephalexin | Cephalexin | 35 | 12 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 35 | suppressed |
| Azithromycin | Azithromycin | 34 | 31 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 34 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Bumetanide | Bumetanide | 33 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 32 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 32 | suppressed |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 11 |
| Temazepam | Temazepam | 30 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 29 | 24 |
| Terazosin Hcl | Terazosin Hcl | 29 | suppressed |
| Valsartan | Valsartan | 29 | suppressed |
| Creon | Lipase/Protease/Amylase | 28 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 28 | 13 |
| Dexlansoprazole Dr | Dexlansoprazole | 28 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 28 | suppressed |
| Gemtesa | Vibegron | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 26 | suppressed |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | suppressed |
| Telmisartan | Telmisartan | 24 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 24 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 23 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 23 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 21 | suppressed |
| Nystatin | Nystatin | 21 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 19 | 17 |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 19 |
| Minocycline Hcl | Minocycline Hcl | 19 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Repatha Syringe | Evolocumab | 19 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Vascepa | Icosapent Ethyl | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Glipizide | Glipizide | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Phenobarbital | Phenobarbital | 18 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 18 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 18 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 17 | suppressed |
| Irbesartan | Irbesartan | 17 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Ranolazine Er | Ranolazine | 14 | suppressed |
| Sulindac | Sulindac | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Haloperidol | Haloperidol | 13 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 12 |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Xcopri | Cenobamate | 13 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Calcitriol | Calcitriol | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Trifluoperazine Hcl | Trifluoperazine Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 11 | 11 |
| Bosentan | Bosentan | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Synjardy | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Telmisartan-Amlodipine | Telmisartan/Amlodipine | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $805.61 · 30 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CT THROMBECTOMY SYSTEM KIT, Cologuard Collection Kit, FANAPT, FARXIGA, FLOWTRIEVER CATHETER, S, Flexitouch Plus, GLYCATE, HETLIOZ, KRYSTEXXA, Korlym, MOUNJARO, NFC-700, NURTEC ODT, Nimbl, OCT OPHTHALMOSCOPE, Omnipod, Ozempic, PANORAMIC OPHTHALMOSCOPE, RELTONE 200 MG, RELTONE 400 MG, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, YUPELRI, ZAVZPRET | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error